Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 543-552

  Martinez Poveda, B ^a   Gomez, V ^a   Alcaide German, M ^a   Perruca, S ^a   Vazquez, S ^a   Alba, L E ^b   Casanovas, O ^c   Garcia Bermejo, M L ^d   Peso, L ^a   Jimenez, Benilde ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiangiogenic treatment; Hypoxia; Optical imaging; Ovarian carcinoma; Xenograft

Indexed keywords

BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR; LUCIFERASE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BIOLUMINESCENCE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NON INVASIVE MEASUREMENT; NONHUMAN; OPTICS; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMAGING, THREE-DIMENSIONAL; LUCIFERASES; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TOMOGRAPHY, OPTICAL; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959925745     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1074     Document Type: Article

References (34)

1. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005. (Pubitemid 43093963)
2. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
3. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
4. Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603, 2008.
5. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338, 2009.
6. Bruick RK and McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF Science 294: 1337-1340, 2001.
7. Epstein AC, Gleadle JM, McNeill LA, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001. (Pubitemid 32972036)
8. Ivan M, Haberberger T, Gervasi DC, et al: Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 99: 13459-13464, 2002. (Pubitemid 35215403)
9. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999. (Pubitemid 29246458)
10. Coleman ML and Ratcliffe PJ: Oxygen sensing and hypoxia-induced responses. Essays Biochem 43: 1-15, 2007.
11. Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D and Medrano EE: Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 61: 8074-8078, 2001. (Pubitemid 33091592)
12. Aragones J, Jones DR, Martin S, et al: Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension. J Biol Chem 276: 10548-10555, 2001.
13. Cecic I, Chan DA, Sutphin PD, et al: Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia. Mol Imaging 6: 219-228, 2007. (Pubitemid 47509826)
14. Liu J, Qu R, Ogura M, Shibata T, Harada H and Hiraoka M: Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo) 46: 93-102, 2005. (Pubitemid 40780154)
15. Ou G, Itasaka S, Zeng L, et al: Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys 75: 463-467, 2009.
16. Rapisarda A, Hollingshead M, Uranchimeg B, et al: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8: 1867-1877, 2009.
17. Rapisarda A, Zalek J, Hollingshead M, et al: Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64: 6845-6848, 2004. (Pubitemid 39330988)
18. Snoeks TJ, Lowik CW and Kaijzel EL: 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis 13: 135-147, 2010.
19. Yeom CJ, Chung JK, Kang JH, et al: Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. J Nucl Med 49: 1489-1497, 2008.
20. Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O and Visakorpi T: Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet 128: 31-34, 2001. (Pubitemid 32655478)
21. Ma J and Waxman DJ: Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 15: 578-588, 2009.
22. Harris AL: Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
23. Cuevas Y, Hernandez-Alcoceba R, Aragones J, et al: Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 63: 6877-6884, 2003. (Pubitemid 37322971)
24. Kizaka-Kondoh S, Itasaka S, Zeng L, et al: Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15: 3433-3441, 2009.
25. Krohn KA, Link JM and Mason RP: Molecular imaging of hypoxia. J Nucl Med 49 (Suppl 2): S129-S148, 2008.
26. Lehmann S, Stiehl DP, Honer M, et al: Longitudinal and multi-modal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci USA 106: 14004-14009, 2009.
27. Raman V, Artemov D, Pathak AP, et al: Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 66: 9929-9936, 2006. (Pubitemid 44672045)
28. Kaelin WG Jr: The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873, 2008.
29. Kondo K, Kim WY, Lechpammer M and Kaelin WG Jr: Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83, 2003.
30. Stiehl DP, Wirthner R Koditz J Spielmann P Camenisch G and Wenger RH: Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an auto-regulatory oxygen-sensing system. J Biol Chem 281: 23482-23491, 2006.
31. Greenaway J, Henkin J, Lawler J, Moorehead R and Petrik J: ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 8: 64-74, 2009.
32. Campbell NE, Greenaway J, Henkin J, Moorehead RA and Petrik J: The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 12: 275-283, 2010.
33. Harada H, Kizaka-Kondoh S and Hiraoka M: Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4: 182-193, 2005. (Pubitemid 43143791)
34. Moroz E, Carlin S, Dyomina K, et al: Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 4: e5077, 2009.